Based on previous studies investigating metabolite concentrations in the disease’s continuum, we hypothesized that we would observe higher mI and lower NAA in participants at higher risk of developing AD (APOE4+, FHD+ or with potentially modifiable risk factors). This evidence concerns the gene APOE and Alzheimer disease.